Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.50 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | TERT | O14746 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12533501 | 0.85 | MAP3K14 (0.69) | MAP3K14HCRTR2CYP19A1AHR | |
| SCHEMBL24393413 | 0.81 | MAP3K14 (0.75) | MAP3K14HCRTR2DRD2DRD3ADRA2A | |
| SCHEMBL16397491 | 0.81 | MAP3K14 (0.75) | MAP3K14HCRTR2DRD2DRD3ADRA2A | |
| SCHEMBL24997240 | 0.81 | MAP3K14 (0.75) | MAP3K14HCRTR2DRD2DRD3ADRA2A | |
| SCHEMBL11170247 | 0.80 | HCRTR2 (0.41) | MAP3K14HCRTR2DRD2DRD3TERT | |
| SCHEMBL11173169 | 0.80 | HCRTR2 (0.41) | MAP3K14HCRTR2DRD2DRD3TERT | |
| SCHEMBL10554627 | 0.80 | HCRTR2 (0.41) | MAP3K14HCRTR2DRD2DRD3TERT | |
| SCHEMBL6899244 | 0.79 | HCRTR2 (0.43) | MAP3K14HCRTR2DRD2DRD3CYP19A1 | |
| SCHEMBL16519791 | 0.79 | HCRTR2 (0.49) | MAP3K14HCRTR2DRD2DRD3TERT | |
| Hydrochloric Acid SCHEMBL10555880 | 0.78 | HCRTR2 (0.41) | MAP3K14HCRTR2DRD2DRD3TERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2491026-A1 | NOVEL HETEROARYL IMIDAZOLES AND HETEROARYL TRIAZOLES AS GAMMA-SECRETASE MODULATORS | Pfizer Inc. (US) | 2012-08-29 | — | — | EP | disclosed |
| US-20120202787-A1 | Novel Heteroaryl Imidazoles And Heteroaryl Triazoles As Gamma-Secretase Modulators | PFIZER INC. | 2012-08-09 | — | — | US | disclosed |
| US-20120053165-A1 | Novel Phenyl Imidazoles and Phenyl Triazoles As Gamma-Secretase Modulators | PFIZER INC. (US) | 2012-03-01 | — | — | US | disclosed |
| EP-2403835-A1 | NOVEL PHENYL IMIDAZOLES AND PHENYL TRIAZOLES AS GAMMA-SECRETASE MODULATORS | Pfizer Inc. (US) | 2012-01-11 | — | — | EP | disclosed |
| WO-2011048525-A1 | NOVEL HETEROARYL IMIDAZOLES AND HETEROARYL TRIAZOLES AS GAMMA-SECRETASE MODULATORS | PFIZER INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| WO-2010100606-A1 | NOVEL PHENYL IMIDAZOLES AND PHENYL TRIAZOLES AS GAMMA-SECRETASE MODULATORS | PFIZER INC. (US) | 2010-09-10 | — | — | WO | disclosed |
| US-3976663-A | INSECTICIDE | THE PROCTER & GAMBLE COMPANY (US) | 1976-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202787-A1 | Novel Heteroaryl Imidazoles And Heteroaryl Triazoles As Gamma-Secretase Modulators | BACE1, BACE2, GSAP | MAP3K14 2548/4885HCRTR2 2405/4885DRD2 4221/4885 |
| US-20120053165-A1 | Novel Phenyl Imidazoles and Phenyl Triazoles As Gamma-Secretase Modulators | BACE1, BACE2, PSEN1 | MAP3K14 1934/4885HCRTR2 2994/4885DRD2 4173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.